Research Studies

Published research on HBOT for Ulcerative Colitis

← Browse all conditions in the PubMed Research Library

These publications include different levels of evidence—not necessarily clinical trials. PubMed indexing is not proof of benefit or an endorsement. Summaries are based on available PubMed abstracts, not a formal full-text quality assessment. Read the limitations as well as the findings; some papers report no benefit or potential harms.

Randomized sham-controlled pilot trial 2018

Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. (opens PubMed in a new tab)

Dulai PS; Buckey JC; Raffals LE; Swoger JM; Claus PL; OʼToole K; Ptak JA; Gleeson MW; Widjaja CE; Chang JT; Adler JM; Patel N; Skinner LA; Haren SP; Goldby-Reffner K; Thompson KD; Siegel CA — The American journal of gastroenterology

Plain English Summary

Hospitalized ulcerative colitis patients receiving HBOT plus steroids had higher early remission rates than those receiving sham plus steroids.

Limitations & context: The trial stopped early because of poor recruitment. It was a small proof-of-concept study requiring larger confirmation.

View on PubMed · PMID 29453383

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting HBOT or any treatment. Individual results may vary.